GlassScriptPhysician profile
Tiffani A Botts
NPI 1316327877
$13,065.04
in general payments reported to CMS, 2019-2025
31 companies · $3,725 in 2025
The $3,725 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,939 · 2022: $1,812 · 2023: $3,191 · 2024: $2,397 · 2025: $3,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,026 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,562 · Consulting Fee: $700 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,026.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,561.90 |
| Consulting Fee | $700.00 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,390.26 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,845.16 | 2021-2025 | Aklief, Twyneo, Oracea |
| Novartis Pharmaceuticals Corporation | $1,115.10 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,066.85 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $854.30 | 2021-2025 | Dupixent |
| Botanix Sb INC | $700.00 | 2025 | Sofdra |
| Merz North America, INC. | $672.75 | 2023-2025 | Xeomin |
| Allergan, INC. | $533.97 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $533.80 | 2021-2024 | |
| Journey Medical Corporation | $466.52 | 2022-2023 | |
| Incyte Corporation | $365.95 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $364.26 | 2021-2025 | Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $259.16 | 2023-2024 | Sotyktu |
| Pfizer INC. | $247.28 | 2021-2024 | |
| Genzyme Corporation | $221.78 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $205.33 | 2021-2023 | Siliq |
| Janssen Biotech, INC. | $178.78 | 2021-2025 | Tremfya |
| Ucb, INC. | $149.06 | 2021-2024 | |
| Madrigal Pharmaceuticals | $148.21 | 2025 | Rezdiffra |
| Organon LLC | $138.73 | 2025 | Vtama |
| Revance Therapeutics, INC. | $135.72 | 2024-2025 | Daxxify |
| Teva Pharmaceuticals USA, INC. | $120.52 | 2025 | Ajovy |
| Amgen INC. | $80.46 | 2025 | Otezla |
| Biofrontera INC. | $50.24 | 2021 | |
| Novo Nordisk INC | $50.00 | 2021 | |
| Gilead Sciences, INC. | $49.50 | 2021 | |
| Genentech USA, INC. | $40.29 | 2021 | |
| Vyne Pharmaceuticals INC. | $39.26 | 2021 | |
| Almirall LLC | $20.26 | 2022 | |
| Currax Pharmaceuticals LLC | $15.36 | 2025 | Contrave |
| Mayne Pharma Commercial LLC | $6.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffani Botts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.